Skip to main content

Table 6 Demographics of study participants in the mITT population—individual and pooled studies 030, 043 and 045

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

  Placebo Tafenoquine 200-mg weekly Total
030 043 045 Pooled 030 043 045 Pooled 030 043 045 Pooled
N 93 60 94 247 99 55 91 245 192 115 185 492
Age (years)
 Median 30 32 48 38 25 34 48 35 27 34 48 36
 Min, max 17, 56 18, 55 17, 60 17, 60 17, 54 18, 54 18, 69 17, 69 17, 56 18, 55 17, 69 17, 69
Age categories (years)
 <20 18 (19.4 %) 13 (21.7 %) 5 (5.3 %) 36 (14.6 %) 19 (19.2 %) 9 (16.4 %) 4 (4.4 %) 32 (13.1 %) 37 (19.3 %) 22 (19.1 %) 9 (4.9 %) 68 (13.8 %)
 20–29 25 (26.9 %) 16 (26.7 %) 14 (14.9 %) 55 (22.3 %) 40 (40.4 %) 15 (27.3 %) 6 (6.6 %) 61 (24.9 %) 65 (33.9 %) 31 (27.0 %) 20 (10.8 %) 116 (23.6 %)
 30–39 23 (24.7 %) 9 (15.0 %) 9 (9.6 %) 41 (16.6 %) 17 (17.2 %) 12 (21.8 %) 20 (22.0 %) 49 (20.0 %) 40 (20.8 %) 21 (18.3 %) 29 (15.7 %) 90 (18.3 %)
 40–49 16 (17.2 %) 19 (31.7 %) 27 (28.7 %) 62 (25.1 %) 12 (12.1 %) 11 (20.0 %) 19 (20.9 %) 42 (17.1 %) 28 (14.6 %) 30 (26.1 %) 46 (24.9 %) 104 (21.1 %)
 ≥50 11 (11.8 %) 3 (5.0 %) 39 (41.5 %) 53 (21.5 %) 11 (11.1 %) 8 (14.5 %) 42 (46.2 %) 61 (24.9 %) 22 (11.5 %) 11 (9.6 %) 81 (43.8 %) 114 (23.2 %)
Sex
 Male 59 (63.4 %) 34 (56.7 %) 62 (66.0 %) 155 (62.8 %) 65 (65.7 %) 38 (69.1 %) 59 (64.8 %) 162 (66.1 %) 124 (64.6 %) 72 (62.6 %) 121 (65.4 %) 317 (64.4 %)
 Female 34 (36.6 %) 26 (43.3 %) 32 (34.0 %) 92 (37.2 %) 34 (34.3 %) 17 (30.9 %) 32 (35.2 %) 83 (33.9 %) 68 (35.4 %) 43 (37.4 %) 64 (34.6 %) 175 (35.6 %)
Height (cm)
 Median NC 169.5 166.5 167 NC 170 166 168 NC 170 166 168
 Min, max   146, 192 150, 189 146, 192   148, 194 149, 188 148, 194   146, 194 149, 189 146, 194
Weight (kg)
 Median 60 60 53 57 60.5 61 50 57 60 60 52 57
 Min, max 44, 81 39, 83 35, 73 35, 83 42, 90 45, 79 35, 68 35, 90 42, 90 39, 83 35, 73 35, 90
  1. Percentages are based on the number of study participants in each treatment group from the mITT population (N)
  2. Max maximum, Min minimum, mITT modified intent-to-treat, N number of subjects, SD standard deviation